Skip to main content

Table 3 Odds ratios and 95% confidence intervals for incidence of TLS using logistic regression models

From: Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

Variables Crude model Model 1 Model 2
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age ≥ 65 years 0.83 (0.30–2.28) 0.720
Male sex 2.75 (0.93–8.10) 0.067 2.29 (0.74–7.12) 0.153
BMI > 22.4 (median value on study population) 0.73 (0.26–2.06) 0.559 0.58 (0.20–1.67) 0.310
Bortezomib-containing therapy 3.10 (0.86–11.10) 0.083 3.11 (0.86–11.30) 0.084 3.40 (0.91–12.70) 0.069
Route for bortezomib administration (Intravenously) 1.82 (0.38–8.64) 0.451 1.92 (0.39–9.37) 0.422
ISS stage III 2.69 (0.98–7.38) 0.055 2.48 (0.88–6.94) 0.085 1.67 (0.50–5.59) 0.409
β2 microglobulin > ULN 0.79 (0.09–6.76) 0.831 0.60 (0.06–5.75) 0.661
Serum albumin > ULN 1.57 (0.42–5.90) 0.501 1.32 (0.33–5.33) 0.698
Lactic dehydrogenase level > ULN 0.93 (0.29–2.99) 0.902 0.91 (0.28–2.96) 0.877
Pretreatment SCr level > ULN 3.32 (1.14–9.09) 0.027 3.20 (1.12–9.19) 0.030 2.09 (0.61–7.16) 0.241
Pretreatment serum uric acid level > ULN 2.56 (0.92–7.14) 0.072 2.11 (0.73–6.08) 0.166 1.71 (0.56–5.20) 0.344
Serum calcium > ULN (presence of hypercalcemia) 1.47 (0.31–6.99) 0.631 1.19 (0.24–5.81) 0.833
Plasma cells in bone marrow (%) 1.00 (0.97–1.03) 0.956 1.00 (0.97–1.03) 0.990
Presence of plasma cell in peripheral blood 0.99 (0.21–4.59) 0.985 0.94 (0.20–1.45) 0.936
Serum free light chain ratio > 1000 1.14 (0.14–9.51) 0.901 0.96 (0.11–8.40) 0.969
Hydration a 1.23 (0.46–3.32) 0.684 1.20 (0.42–3.45) 0.729
Urine alkalization 1.14 (0.31–4.28) 0.843 1.07 (0.28–4.16) 0.919
  1. Model 1: Adjusted for age and sex, Model 2: Adjusted for the variables that had P-values < 0.100 in a crude model
  2. TLS Tumor lysis syndrome, OR Odds ratio, CI Confidence interval, ISS International Staging System, SCr serum creatinine, BMI Body mass index, ULN Upper limit of normal range
  3. aDefined as the average infusion volume over 1000 mL / day for eight days (from one day before to 7 days after the initiation of multiple myeloma primary treatment)
\